On the public citation graph

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status

https://doi.org/10.3390/jcm9040940
0 signed · 166 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamaoncol.2015.0735openalex-snapshot
The Global Burden of Cancer 2013
inferredcites →https://doi.org/10.1002/(sici)1097-0215(19980821)79:4<334::aid-ijc5>3.0.co;2-wopenalex-snapshot
An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers
inferredcites →https://doi.org/10.1002/jcb.25229openalex-snapshot
Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells
inferredcites →https://doi.org/10.1007/s00018-019-03120-6openalex-snapshot
Novel insights into PARPs in gene expression: regulation of RNA metabolism
inferredcites →https://doi.org/10.1007/s11523-019-00629-5openalex-snapshot
Rucaparib: A Review in Ovarian Cancer
inferredcites →https://doi.org/10.1016/j.ceb.2008.03.006openalex-snapshot
Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation
inferredcites →https://doi.org/10.1016/j.molonc.2010.04.004openalex-snapshot
Histological types of breast cancer: How special are they?
inferredcites →https://doi.org/10.1021/cb300317yopenalex-snapshot
Identification of Pim Kinases as Novel Targets for PJ34 with Confounding Effects in PARP Biology
inferredcites →https://doi.org/10.1038/378789a0openalex-snapshot
Identification of the breast cancer susceptibility gene BRCA2
inferredcites →https://doi.org/10.1038/nature10933openalex-snapshot
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
inferredcites →https://doi.org/10.1038/nature11412openalex-snapshot
Comprehensive molecular portraits of human breast tumours
inferredcites →https://doi.org/10.1038/nature18003openalex-snapshot
Proteogenomics connects somatic mutations to signalling in breast cancer
inferredcites →https://doi.org/10.1038/ng0495-444openalex-snapshot
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression
inferredcites →https://doi.org/10.1038/ng1294-392openalex-snapshot
Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families
inferredcites →https://doi.org/10.1038/nm.4292openalex-snapshot
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
inferredcites →https://doi.org/10.1038/nrc3181openalex-snapshot
BRCA1 and BRCA2: different roles in a common pathway of genome protection
inferredcites →https://doi.org/10.1038/s41540-017-0011-6openalex-snapshot
Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm
inferredcites →https://doi.org/10.1056/nejmoa1706450openalex-snapshot
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
inferredcites →https://doi.org/10.1056/nejmoa1802905openalex-snapshot
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
inferredcites →https://doi.org/10.1074/jbc.m114.551143openalex-snapshot
Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors
inferredcites →https://doi.org/10.1097/gim.0b013e3181d38f2fopenalex-snapshot
Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
inferredcites →https://doi.org/10.1101/gad.16962311openalex-snapshot
The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes
inferredcites →https://doi.org/10.1126/science.1216338openalex-snapshot
Structural Basis for DNA Damage–Dependent Poly(ADP-ribosyl)ation by Human PARP-1
inferredcites →https://doi.org/10.1126/science.282.5393.1484openalex-snapshot
Tankyrase, a Poly(ADP-Ribose) Polymerase at Human Telomeres
inferredcites →https://doi.org/10.1126/science.7545954openalex-snapshot
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
inferredcites →https://doi.org/10.1126/scitranslmed.aaf9246openalex-snapshot
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
inferredcites →https://doi.org/10.1158/0008-5472.can-05-2853openalex-snapshot
BRCA1 Mutation Analysis of 41 Human Breast Cancer Cell Lines Reveals Three New Deleterious Mutants
inferredcites →https://doi.org/10.1158/0008-5472.can-06-0140openalex-snapshot
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
inferredcites →https://doi.org/10.1158/0008-5472.can-06-0503openalex-snapshot
Prevalence and Predictors of BRCA1 and BRCA2 Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years
inferredcites →https://doi.org/10.1158/0008-5472.can-12-1470openalex-snapshot
Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
inferredcites →https://doi.org/10.1158/0008-5472.can-12-2753openalex-snapshot
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
inferredcites →https://doi.org/10.1158/0008-5472.can-13-2541openalex-snapshot
Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
inferredcites →https://doi.org/10.1158/1078-0432.ccr-09-0636openalex-snapshot
Resistance to Trastuzumab in Breast Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-16-1040openalex-snapshot
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
inferredcites →https://doi.org/10.1158/1535-7163.1585.3.12openalex-snapshot
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer
inferredcites →https://doi.org/10.1158/1535-7163.mct-13-0803openalex-snapshot
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
inferredcites →https://doi.org/10.1158/1535-7163.mct-17-0760openalex-snapshot
Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer
inferredcites →https://doi.org/10.1158/1541-7786.mcr-15-0191-topenalex-snapshot
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors
inferredcites →https://doi.org/10.1158/1541-7786.mcr-18-0138openalex-snapshot
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
inferredcites →https://doi.org/10.1158/2159-8290.cd-11-0206openalex-snapshot
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
inferredcites →https://doi.org/10.1159/000353099openalex-snapshot
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
inferredcites →https://doi.org/10.1159/000453569openalex-snapshot
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
inferredcites →https://doi.org/10.1186/bcr2445openalex-snapshot
A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors
inferredcites →https://doi.org/10.1186/bcr2780openalex-snapshot
Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups
inferredcites →https://doi.org/10.1200/jco.20.3.719openalex-snapshot
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
inferredcites →https://doi.org/10.1200/jco.2002.20.3.719openalex-snapshot
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
inferredcites →https://doi.org/10.1371/journal.pone.0078259openalex-snapshot
Triple Negative Breast Tumors in African-American and Hispanic/Latina Women Are High in CD44+, Low in CD24+, and Have Loss of PTEN
inferredcites →https://doi.org/10.1615/critreveukaryotgeneexpr.2013006875openalex-snapshot
Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases
inferredcites →https://doi.org/10.2147/ott.s184971openalex-snapshot
Evidence to date: talazoparib in the treatment of breast cancer
inferredcites →https://doi.org/10.3389/fphar.2018.00909openalex-snapshot
Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis
inferredcites →https://doi.org/10.3390/jcm8040435openalex-snapshot
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
inferredcites →https://doi.org/10.3892/ijo.14.6.1021openalex-snapshot
Prognostic value of plasma HER-2/neu in African American and Hispanic women with breast cancer.

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4677489openalex-extracted
inferred← citeshttps://doi.org/10.1002/2211-5463.13917openalex-snapshot
Interaction of RECQL 4 with poly( ADP ‐ribose) is critical for the DNA double‐strand break response in human cells
inferred← citeshttps://doi.org/10.1002/advs.202410718openalex-snapshot
Targeting Replication Fork Processing Synergizes with PARP Inhibition to Potentiate Lethality in Homologous Recombination Proficient Ovarian Cancers
inferred← citeshttps://doi.org/10.1002/ardp.202300599openalex-snapshot
Phthalimide‐tethered isatins as novel poly(ADP‐ribose) polymerase inhibitors: Design, synthesis, biological evaluations, and molecular modeling investigations
inferred← citeshttps://doi.org/10.1002/cnr2.70119openalex-snapshot
PARP ‐1 Inhibition Increases Oxidative Stress in Ets‐1‐Expressing MDA ‐ MB ‐231 Breast Cancer Cells
inferred← citeshttps://doi.org/10.1002/iub.2773openalex-snapshot
Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy
inferred← citeshttps://doi.org/10.1002/jcp.31015openalex-snapshot
Triumphs and challenges in exploiting poly(ADP‐ribose) polymerase inhibition to combat triple‐negative breast cancer
inferred← citeshttps://doi.org/10.1002/med.22058openalex-snapshot
Poly (adenosine diphosphate‐ribose) polymerase inhibitors in the treatment of triple‐negative breast cancer with homologous repair deficiency
inferred← citeshttps://doi.org/10.1007/978-981-15-4501-6_119-1openalex-snapshot
Targeting Redox Signaling and ROS Metabolism in Cancer Treatment
inferred← citeshttps://doi.org/10.1007/978-981-15-9411-3_119openalex-snapshot
Targeting Redox Signaling and ROS Metabolism in Cancer Treatment
inferred← citeshttps://doi.org/10.1007/s10549-023-07150-4openalex-snapshot
Olaparib enhances sensitization of BRCA-proficient breast cancer cells to x-rays and protons
inferred← citeshttps://doi.org/10.1007/s10637-021-01116-3openalex-snapshot
Successful treatment of an adult patient with diffuse midline glioma employing olaparib combined with bevacizumab
inferred← citeshttps://doi.org/10.1007/s11845-025-04240-8openalex-snapshot
Resveratrol potentiates chemotherapeutic efficacy of olaparib in MCF7 human breast cancer cells by inducing apoptosis
inferred← citeshttps://doi.org/10.1016/b978-0-12-824476-0.00017-6openalex-snapshot
Basics of targeted nanodrug delivery of chemotherapeutics for breast cancer therapy
inferred← citeshttps://doi.org/10.1016/b978-0-443-33536-5.00004-3openalex-snapshot
The genetic puzzle: BRCA mutations and personalized medicine
inferred← citeshttps://doi.org/10.1016/j.apsb.2024.03.012openalex-snapshot
Precise nano-system-based drug delivery and synergistic therapy against androgen receptor-positive triple-negative breast cancer
inferred← citeshttps://doi.org/10.1016/j.bbadis.2024.167213openalex-snapshot
Loss of cytidine deaminase expression as a potential attempt to counteract the process of carcinogenesis by reducing basal PARP-1 activity and increasing tau levels
inferred← citeshttps://doi.org/10.1016/j.bbadis.2024.167537openalex-snapshot
Nuclear localization of APLF facilitates breast cancer metastasis
inferred← citeshttps://doi.org/10.1016/j.bcp.2024.116045openalex-snapshot
A review of poly(ADP-ribose)polymerase-1 (PARP1) role and its inhibitors bearing pyrazole or indazole core for cancer therapy
inferred← citeshttps://doi.org/10.1016/j.bioorg.2024.107924openalex-snapshot
Synergy trap for guardian angels of DNA: Unraveling the anticancer potential of phthalazinone-thiosemicarbazone hybrids through dual PARP-1 and TOPO-I inhibition
inferred← citeshttps://doi.org/10.1016/j.ccr.2024.215774openalex-snapshot
Recent updates in nanoscale delivery systems of platinum(IV) antitumor prodrugs
inferred← citeshttps://doi.org/10.1016/j.celrep.2023.113256openalex-snapshot
Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages
inferred← citeshttps://doi.org/10.1016/j.celrep.2024.114433openalex-snapshot
ADP-ribosylome analysis reveals homogeneous DNA-damage-induced serine ADP-ribosylation across wild-type and BRCA-mutant breast cancer cell lines
inferred← citeshttps://doi.org/10.1016/j.clicom.2023.06.002openalex-snapshot
Aptamer: A theranostic approach towards breast cancer
inferred← citeshttps://doi.org/10.1016/j.dnarep.2020.103023openalex-snapshot
Zebrafish as an in vivo screening tool to establish PARP inhibitor efficacy
inferred← citeshttps://doi.org/10.1016/j.drudis.2022.02.002openalex-snapshot
Exclusive modifications of NuMA in malignant epithelial cells: A potential therapeutic mechanism
inferred← citeshttps://doi.org/10.1016/j.ebiom.2022.104205openalex-snapshot
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
inferred← citeshttps://doi.org/10.1016/j.gendis.2025.101817openalex-snapshot
Targeting fatty acid synthase to overcome PARP inhibitor resistance and to create an artificial synthetic lethality for triple-negative breast cancer
inferred← citeshttps://doi.org/10.1016/j.ijpharm.2022.121897openalex-snapshot
A DNA damage nanoamplifier for the chemotherapy of triple-negative breast cancer via DNA damage induction and repair blocking
inferred← citeshttps://doi.org/10.1016/j.jprot.2023.104823openalex-snapshot
PARP inhibitor olaparib induced differential protein expression in cervical cancer cells
inferred← citeshttps://doi.org/10.1016/j.molcel.2025.10.026openalex-snapshot
HSP90 buffers deleterious genetic variations in BRCA1
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2021.107800openalex-snapshot
Trailblazing perspectives on targeting breast cancer stem cells
inferred← citeshttps://doi.org/10.1016/j.prp.2021.153557openalex-snapshot
Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.prp.2025.156338openalex-snapshot
The advancements in targeted therapeutic strategies for breast cancer via intervention of natural molecules: An insight into cellular and molecular mechanisms
inferred← citeshttps://doi.org/10.1016/j.yexcr.2023.113487openalex-snapshot
m6A reader HNRNPA2B1 destabilization of ATG4B regulates autophagic activity, proliferation and olaparib sensitivity in breast cancer
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.1c00903openalex-snapshot
DoE Optimization Empowers the Automated Preparation of Enantiomerically Pure [ 18 F]Talazoparib and its In Vivo Evaluation as a PARP Radiotracer
inferred← citeshttps://doi.org/10.1038/s12276-021-00557-3openalex-snapshot
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
inferred← citeshttps://doi.org/10.1038/s41388-022-02497-2openalex-snapshot
A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming
inferred← citeshttps://doi.org/10.1038/s41416-020-01238-0openalex-snapshot
Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition
inferred← citeshttps://doi.org/10.1038/s41419-021-03475-4openalex-snapshot
Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer
inferred← citeshttps://doi.org/10.1038/s41419-021-04405-0openalex-snapshot
MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance
inferred← citeshttps://doi.org/10.1038/s41419-024-07009-6openalex-snapshot
PINX1 loss confers susceptibility to PARP inhibition in pan-cancer cells
inferred← citeshttps://doi.org/10.1038/s41419-025-07868-7openalex-snapshot
The post-translational modification of NuMA in cancer cells is a new target for cancer eradication
inferred← citeshttps://doi.org/10.1038/s41419-026-08583-7openalex-snapshot
AdipoR1–AMPK axis suppresses breast cancer across molecular subtypes via multimodal cell death pathways, including ferroptosis and apoptosis
inferred← citeshttps://doi.org/10.1038/s41467-022-30311-wopenalex-snapshot
Synthetic lethality between TP53 and ENDOD1
inferred← citeshttps://doi.org/10.1038/s41523-023-00568-5openalex-snapshot
Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer
inferred← citeshttps://doi.org/10.1038/s41597-024-03018-4openalex-snapshot
Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries
inferred← citeshttps://doi.org/10.1038/s41598-021-87998-yopenalex-snapshot
Selection of aptamers against triple negative breast cancer cells using high throughput sequencing
inferred← citeshttps://doi.org/10.1038/s44321-024-00094-2openalex-snapshot
FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer
inferred← citeshttps://doi.org/10.1039/d1an01769aopenalex-snapshot
Quantitative analysis of biochemical processes in living cells at a single-molecule level: a case of olaparib–PARP1 (DNA repair protein) interactions
inferred← citeshttps://doi.org/10.1093/nar/gkad659openalex-snapshot
Absence of mitochondrial SLC25A51 enhances PARP1-dependent DNA repair by increasing nuclear NAD+ levels
inferred← citeshttps://doi.org/10.1097/md.0000000000050561openalex-snapshot
Successful treatment of a large-sized triple-negative breast cancer
inferred← citeshttps://doi.org/10.1101/2020.10.14.339309openalex-snapshot
Synthetic lethality between TP53 and ENDOD1
inferred← citeshttps://doi.org/10.1101/2023.07.06.547853openalex-snapshot
Homologous recombination deficiency in cell line libraries does not correlate with in vitro sensitivity to platinum agents or PARP inhibitors
inferred← citeshttps://doi.org/10.1101/2023.12.15.571635openalex-snapshot
A Site-Specific Analysis of the ADP-Ribosylome Unveils Homogeneous DNA Damage-Induced Serine ADP-Ribosylation Across Wild-Type and BRCA-Mutant Breast Cancer Cell Lines
inferred← citeshttps://doi.org/10.1101/2024.05.15.594427openalex-snapshot
Unraveling systemic responses to NQO1-activated IB-DNQ and Rucaparib single and dual agent therapy in triple-negative breast cancers
inferred← citeshttps://doi.org/10.1101/2024.11.15.623783openalex-snapshot
HSP90 buffers deleterious genetic variations in BRCA1
inferred← citeshttps://doi.org/10.1111/cas.70058openalex-snapshot
Pimitespib, an HSP90 Inhibitor, Enhances the Efficacy of PARP Inhibitors in PARP Inhibitor‐Insensitive Breast Cancer Cells
inferred← citeshttps://doi.org/10.1111/febs.16615openalex-snapshot
Identification and characterization of mercaptopyrimidine‐based small molecules as inhibitors of nonhomologous DNA end joining
inferred← citeshttps://doi.org/10.1158/0008-5472.can-20-2685openalex-snapshot
E2A Modulates Stemness, Metastasis, and Therapeutic Resistance of Breast Cancer
inferred← citeshttps://doi.org/10.1158/0008-5472.can-23-0485openalex-snapshot
Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma
inferred← citeshttps://doi.org/10.1158/0008-5472.can-23-3458openalex-snapshot
PARP-ish: Gaps in Molecular Understanding and Clinical Trials Targeting PARP Exacerbate Racial Disparities in Prostate Cancer
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-22-1602openalex-snapshot
[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
inferred← citeshttps://doi.org/10.1158/1541-7786.mcr-21-0103openalex-snapshot
PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor α–Positive Breast Cancer Cells
inferred← citeshttps://doi.org/10.1158/2767-9764.crc-21-0064openalex-snapshot
BRCA1/ATF1-Mediated Transactivation is Involved in Resistance to PARP Inhibitors and Cisplatin
inferred← citeshttps://doi.org/10.1159/000525281openalex-snapshot
PARP Inhibition and Beyond in BRCA-Associated Breast Cancer in Women: A State-Of-The-Art Summary of Preclinical Research on Risk Reduction and Clinical Benefits
inferred← citeshttps://doi.org/10.1177/15330338221145246openalex-snapshot
Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review
inferred← citeshttps://doi.org/10.1186/s13046-020-01694-9openalex-snapshot
Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
inferred← citeshttps://doi.org/10.1186/s13046-021-02039-wopenalex-snapshot
Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors
inferred← citeshttps://doi.org/10.1186/s13065-025-01389-2openalex-snapshot
Multi-stage structure-based virtual screening approach combining 3D pharmacophore, docking and molecular dynamic simulation towards the identification of potential selective PARP-1 inhibitors
inferred← citeshttps://doi.org/10.1186/s40816-025-00406-0openalex-snapshot
Nature’s touch in oncology: evidence based approach exploring phytoscience for emerging therapeutics of breast cancer
inferred← citeshttps://doi.org/10.1200/po.21.00152openalex-snapshot
PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations
inferred← citeshttps://doi.org/10.1371/journal.pone.0247837openalex-snapshot
The overexpression of DNA repair genes in invasive ductal and lobular breast carcinomas: Insights on individual variations and precision medicine
inferred← citeshttps://doi.org/10.14393/ufu.te.2020.760openalex-snapshot
Vitamina D3: Potencial modulador sobre a Mutagenicidade e a Carcinogenicidade induzida por Doxorrubicina em Drosophila melanogaster e sinergismo com fármacos em sistema in vitro
inferred← citeshttps://doi.org/10.1515/chem-2025-0203openalex-snapshot
Potential anticancer agents from genus Aerva based on tubulin targets: an in-silico integration of quantitative structure activity relationship (QSAR), molecular docking, simulation, drug-likeness, and density functional theory (DFT) analysis
inferred← citeshttps://doi.org/10.18632/oncotarget.28047openalex-snapshot
Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1105292/v1openalex-snapshot
Development and Validation of a Prognostic Classifier Based on Metabolism-Related Genes for Breast Cancer
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2525620/v1openalex-snapshot
Niraparib enhances radiosensitivity in glioblastoma with redistribution of DDX21
inferred← citeshttps://doi.org/10.21203/rs.3.rs-48785/v1openalex-snapshot
GSK3β Inhibition Synergizes with PARP Inhibitors through the Induction of Homologous Recombination Deficiency in Colorectal Cancer
inferred← citeshttps://doi.org/10.2147/jir.s357144openalex-snapshot
Development and Validation of a Prognostic Classifier Based on Lipid Metabolism-Related Genes for Breast Cancer
inferred← citeshttps://doi.org/10.2174/0929867329666220726153412openalex-snapshot
The Association Between the Risk of Breast Cancer and Epigallocatechin- 3-Gallate Intake: A Literature Review of a Potential Chemopreventive Agent
inferred← citeshttps://doi.org/10.26508/lsa.202101144openalex-snapshot
Suppression of isoprenylcysteine carboxylmethyltransferase compromises DNA damage repair
inferred← citeshttps://doi.org/10.2967/jnumed.124.268254openalex-snapshot
Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate–Ribose) Polymerase-1–Targeted18F-Fluorthanatrace PET in Breast Cancer
inferred← citeshttps://doi.org/10.3389/fgene.2025.1589259openalex-snapshot
Impact of ITH on PRAD patients and feasibility analysis of the positive correlation gene MYLK2 applied to PRAD treatment
inferred← citeshttps://doi.org/10.3389/fonc.2021.798296openalex-snapshot
Spatial Profiling Identifies Prognostic Features of Response to Adjuvant Therapy in Triple Negative Breast Cancer (TNBC)
inferred← citeshttps://doi.org/10.3389/fonc.2022.938561openalex-snapshot
Implementation of multigene panel testing for breast and ovarian cancer in South Africa: A step towards excellence in oncology for the public sector
inferred← citeshttps://doi.org/10.3390/biom13101480openalex-snapshot
Combination Treatment Strategies to Overcome PARP Inhibitor Resistance
inferred← citeshttps://doi.org/10.3390/biom14060625openalex-snapshot
BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy
inferred← citeshttps://doi.org/10.3390/biomedicines11082090openalex-snapshot
Combination Therapy with Trastuzumab and Niraparib: Quantifying Early Proliferative Alterations in HER2+ Breast Cancer Models
inferred← citeshttps://doi.org/10.3390/biomedicines12071617openalex-snapshot
Expanding the Perspective on PARP1 and Its Inhibitors in Cancer Therapy: From DNA Damage Repair to Immunomodulation
inferred← citeshttps://doi.org/10.3390/cancers12061628openalex-snapshot
The Modified Phenanthridine PJ34 Unveils an Exclusive Cell-Death Mechanism in Human Cancer Cells
inferred← citeshttps://doi.org/10.3390/cancers12071769openalex-snapshot
Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status
inferred← citeshttps://doi.org/10.3390/cancers13071656openalex-snapshot
Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration
inferred← citeshttps://doi.org/10.3390/cancers14010230openalex-snapshot
Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study
inferred← citeshttps://doi.org/10.3390/cancers14061533openalex-snapshot
Is There a Role for Epigenetic Therapies in Modulating DNA Damage Repair Pathways to Enhance Chemotherapy and Overcome Drug Resistance?
inferred← citeshttps://doi.org/10.3390/cancers14153661openalex-snapshot
The Differential Metabolic Signature of Breast Cancer Cellular Response to Olaparib Treatment
inferred← citeshttps://doi.org/10.3390/cancers15041299openalex-snapshot
Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer
inferred← citeshttps://doi.org/10.3390/cancers15072010openalex-snapshot
Aptamer-Based Strategies to Boost Immunotherapy in TNBC
inferred← citeshttps://doi.org/10.3390/cancers16030595openalex-snapshot
Molecular Basis of XRN2-Deficient Cancer Cell Sensitivity to Poly(ADP-ribose) Polymerase Inhibition
inferred← citeshttps://doi.org/10.3390/cells13010049openalex-snapshot
The Sensitization of Triple-Negative Breast Cancers to Poly ADP Ribose Polymerase Inhibition Independent of BRCA1/2 Mutation Status by Chemically Modified microRNA-489
inferred← citeshttps://doi.org/10.3390/genes11111251openalex-snapshot
BARD1 and Breast Cancer: The Possibility of Creating Screening Tests and New Preventive and Therapeutic Pathways for Predisposed Women
inferred← citeshttps://doi.org/10.3390/ijms21134579openalex-snapshot
Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
inferred← citeshttps://doi.org/10.3390/ijms232416171openalex-snapshot
PARP Inhibitor Inhibits the Vasculogenic Mimicry through a NF-κB-PTX3 Axis Signaling in Breast Cancer Cells
inferred← citeshttps://doi.org/10.3390/ijms25063254openalex-snapshot
Efficacy of Cold Atmospheric Plasma vs. Chemotherapy in Triple-Negative Breast Cancer: A Systematic Review
inferred← citeshttps://doi.org/10.3390/ijms27198557openalex-snapshot
In Vitro Anticancer Activity and Integrated Multi-Target Computational Analysis of Ylang-Ylang Essential Oil Against Breast Cancer
inferred← citeshttps://doi.org/10.3390/jcm12041375openalex-snapshot
Understanding Breast Cancer Aggressiveness and Its Implications in Diagnosis and Treatment
inferred← citeshttps://doi.org/10.3390/jcm9082377openalex-snapshot
Enhance PARPi Application beyond BRCA-Mutant Breast Cancer (BC): Facts Are Facts
inferred← citeshttps://doi.org/10.3390/jpm11101009openalex-snapshot
PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer
inferred← citeshttps://doi.org/10.3390/molecules29061407openalex-snapshot
Discovery of Novel 4-Hydroxyquinazoline Derivatives: In Silico, In Vivo and In Vitro Studies Using Primary PARPi-Resistant Cell Lines
inferred← citeshttps://doi.org/10.3390/ph14060589openalex-snapshot
Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
inferred← citeshttps://doi.org/10.3390/ph15091075openalex-snapshot
Combination of Talazoparib and Calcitriol Enhanced Anticancer Effect in Triple−Negative Breast Cancer Cell Lines
inferred← citeshttps://doi.org/10.34172/biomedrb.2023.27openalex-snapshot
Effects of Sacituzumab on Breast Cancer: Target Therapy
inferred← citeshttps://doi.org/10.6084/m9.figshare.15040914openalex-snapshot
Additional file 1 of Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors
inferred← citeshttps://doi.org/10.70675/39dada9azb659z4d43z88d9z13c1fa14c3c7openalex-snapshot
Rôle du récepteur LRP-1 dans la croissance tumorale et l’angiogenèse associée dans un modèle de cancer mammaire triple négatif
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.